Evercore ISI analyst Vijay Kumar has maintained their bullish stance on ABT stock, giving a Buy rating today.
Vijay Kumar has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ robust performance and strategic positioning. The company reported a strong organic growth rate of 6.9% in the first quarter, with significant contributions from various segments such as electrophysiology and continuous glucose monitoring. This broad-based growth, coupled with a notable EPS increase of approximately 11%, underscores Abbott’s ability to maintain financial health amidst challenging macroeconomic conditions.
Looking ahead, Abbott’s management has reiterated its guidance for 7.5-8.5% organic growth and an EPS range of $5.05-$5.25 for the fiscal year 2025. The company’s diversified business model and strategic levers, including potential tariff impacts and interest income, provide a cushion against market volatility. Additionally, Abbott’s strong balance sheet with low net leverage further supports its resilience. These factors, along with ongoing growth drivers and potential litigation settlements, make Abbott Laboratories a compelling investment choice in uncertain times.
According to TipRanks, Kumar is a 2-star analyst with an average return of -0.2% and a 45.27% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Illumina, Abbott Laboratories, and Baxter International.
In another report released today, J.P. Morgan also reiterated a Buy rating on the stock with a $135.00 price target.